Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session. Crude didn't have as good a day, though, plumbing fresh three-month lows. Drugmaker AstraZeneca (AZN) jumped on a better-than-expected second quarter. Sales of new drug treatments helped to offset declining revenue from cholesterol drug Crestor which has seen generic competition crop up after its patent expired. Deutsche Bank made the case for Bank of America (BAC) in a bullish note, favoring the North Carolinian institute over competitor JPMorgan (JPM) . Analysts said Bank of America is better positioned with less consumer credit risk. Match (MTCH) declined after warning investors of slowing growth. Even so, the company did manage a 41 percent increase in second-quarter profit thanks to strength in its dating app Tinder.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.